JP2005502357A - 細胞培養物中のウイルス増殖 - Google Patents

細胞培養物中のウイルス増殖 Download PDF

Info

Publication number
JP2005502357A
JP2005502357A JP2003527090A JP2003527090A JP2005502357A JP 2005502357 A JP2005502357 A JP 2005502357A JP 2003527090 A JP2003527090 A JP 2003527090A JP 2003527090 A JP2003527090 A JP 2003527090A JP 2005502357 A JP2005502357 A JP 2005502357A
Authority
JP
Japan
Prior art keywords
virus
cells
medium
culture
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003527090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502357A5 (cg-RX-API-DMAC10.html
Inventor
ユルゲン フォアロープ，
クリスチャン フレッヒ，
ホルガー リュッベン，
イェンスーペーター グレーゲルゼン，
Original Assignee
カイロン ベーリング ゲーエムベーハー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン ベーリング ゲーエムベーハー アンド カンパニー filed Critical カイロン ベーリング ゲーエムベーハー アンド カンパニー
Publication of JP2005502357A publication Critical patent/JP2005502357A/ja
Publication of JP2005502357A5 publication Critical patent/JP2005502357A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2003527090A 2001-09-12 2002-09-11 細胞培養物中のウイルス増殖 Pending JP2005502357A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
PCT/EP2002/010207 WO2003023025A1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010145663A Division JP2010246559A (ja) 2001-09-12 2010-06-25 細胞培養物中のウイルス増殖

Publications (2)

Publication Number Publication Date
JP2005502357A true JP2005502357A (ja) 2005-01-27
JP2005502357A5 JP2005502357A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=7698761

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003527090A Pending JP2005502357A (ja) 2001-09-12 2002-09-11 細胞培養物中のウイルス増殖
JP2010145663A Pending JP2010246559A (ja) 2001-09-12 2010-06-25 細胞培養物中のウイルス増殖

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010145663A Pending JP2010246559A (ja) 2001-09-12 2010-06-25 細胞培養物中のウイルス増殖

Country Status (16)

Country Link
US (1) US20050118698A1 (cg-RX-API-DMAC10.html)
EP (1) EP1427817B1 (cg-RX-API-DMAC10.html)
JP (2) JP2005502357A (cg-RX-API-DMAC10.html)
KR (1) KR100968141B1 (cg-RX-API-DMAC10.html)
AT (1) ATE466932T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002338666B2 (cg-RX-API-DMAC10.html)
BR (1) BR0212469A (cg-RX-API-DMAC10.html)
CA (1) CA2456561A1 (cg-RX-API-DMAC10.html)
CY (1) CY1110716T1 (cg-RX-API-DMAC10.html)
DE (2) DE10144903A1 (cg-RX-API-DMAC10.html)
DK (1) DK1427817T3 (cg-RX-API-DMAC10.html)
ES (1) ES2345606T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ532203A (cg-RX-API-DMAC10.html)
PT (1) PT1427817E (cg-RX-API-DMAC10.html)
SI (1) SI1427817T1 (cg-RX-API-DMAC10.html)
WO (1) WO2003023025A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502692A (ja) * 2006-09-11 2010-01-28 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
JP2013507952A (ja) * 2009-10-20 2013-03-07 ノバルティス アーゲー ウイルスレスキューのための改善された逆遺伝学
JP2014506795A (ja) * 2011-02-17 2014-03-20 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｒｒｓｖの工業規模の製造方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005245943A1 (en) * 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
EP2686423A4 (en) 2011-03-14 2015-01-28 Nat Res Council Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CN104159608A (zh) 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
US20150210986A1 (en) * 2012-08-24 2015-07-30 Ge Healthcare Bio-Sciences Corp. Virus purification and formulation process
KR101370512B1 (ko) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
CN115927755A (zh) * 2022-11-22 2023-04-07 辽宁成大生物股份有限公司 一种微量水痘-带状疱疹病毒的检测方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064846A1 (fr) * 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
EP0878541A4 (en) * 1996-10-18 2001-10-17 Univ Osaka Res Found ROTAVIRUS ANTIGENS, VACCINALS AND MEDICATIONS AGAINST INFECTION BY ROTAVIRUS, AND METHOD FOR THEIR PRODUCTION
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064846A1 (fr) * 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502692A (ja) * 2006-09-11 2010-01-28 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
JP2016074747A (ja) * 2006-09-11 2016-05-12 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
JP2019011344A (ja) * 2006-09-11 2019-01-24 セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ 卵を使用しないインフルエンザウイルスワクチンの作製
JP2022034076A (ja) * 2006-09-11 2022-03-02 セキラス ユーケー リミテッド 卵を使用しないインフルエンザウイルスワクチンの作製
JP7260270B2 (ja) 2006-09-11 2023-04-18 セキラス ユーケー リミテッド 卵を使用しないインフルエンザウイルスワクチンの作製
JP2023093728A (ja) * 2006-09-11 2023-07-04 セキラス ユーケー リミテッド 卵を使用しないインフルエンザウイルスワクチンの作製
JP7427648B2 (ja) 2006-09-11 2024-02-05 セキラス ユーケー リミテッド 卵を使用しないインフルエンザウイルスワクチンの作製
JP2013507952A (ja) * 2009-10-20 2013-03-07 ノバルティス アーゲー ウイルスレスキューのための改善された逆遺伝学
JP2014506795A (ja) * 2011-02-17 2014-03-20 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｒｒｓｖの工業規模の製造方法

Also Published As

Publication number Publication date
WO2003023025A1 (de) 2003-03-20
DE50214416D1 (de) 2010-06-17
AU2002338666B2 (en) 2008-11-20
NZ532203A (en) 2005-04-29
EP1427817B1 (de) 2010-05-05
EP1427817A1 (de) 2004-06-16
CA2456561A1 (en) 2003-03-20
DE10144903A1 (de) 2003-03-27
ES2345606T3 (es) 2010-09-28
ATE466932T1 (de) 2010-05-15
HK1062029A1 (zh) 2004-10-15
CY1110716T1 (el) 2015-06-10
KR100968141B1 (ko) 2010-07-06
PT1427817E (pt) 2010-08-10
DK1427817T3 (da) 2010-08-23
JP2010246559A (ja) 2010-11-04
SI1427817T1 (sl) 2010-08-31
US20050118698A1 (en) 2005-06-02
BR0212469A (pt) 2004-08-24
KR20050027164A (ko) 2005-03-17

Similar Documents

Publication Publication Date Title
JP5264812B2 (ja) Ｍｄｃｋ細胞懸濁培養物において薬物または診断剤の活性成分を生成する方法
AU2002338666B2 (en) Multiplication of viruses in a cell culture
JP5264843B2 (ja) 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス
JP4243349B2 (ja) インフルエンザウイルスの複製のための動物細胞および方法
FI121117B (fi) Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä
JP4331432B2 (ja) ワクチンの生成方法
JP2004509903A (ja) 生ワクチン及び製造方法
WO2007132763A1 (ja) インフルエンザウイルスの増殖方法
HK1062029B (en) Multiplication of viruses in a cell culture
HK1149046A (en) Method for manufacturing an active component of a medicine or diagnosis agent in mdcj cell suspension culture
HK1062030B (en) Methods for the industrial production of vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090515

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100625

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100819

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100917